Treatment with Different Doses of Candesartan in Acute Pancreatitis Model
YAN Jun,LI Chuang,QIU Wen-cai,YUAN Qing-ling,WANG Zhi-gang,ZHENG Qi
DOI: https://doi.org/10.3969/j.issn.1009-9905.2011.02.005
2011-01-01
Abstract:Objective: To investigate the selective AT1 subtype angiotensin Ⅱ receptor antagonist candesartan dose on acute pancreatitis(acute pancreatitis,AP) effect.Methods: 72 male SD rats were randomly divided into normal control group,AP group,AP + low-dose candesartan group(2 mg/kg),AP+candesartan high dose group(10 mg/kg);intraperitoneal injection of 20% L-arginine solution established animal model of AP;candesartan in rats fed with needle perfusion.Rats in each group,respectively 12,24,48 hours after modeling the number of batches,(6/group/batch) heart blood to death.Pancreas tissue and pathological changes of pancreas were observed score(by Rongione standard),pancreas/ body weight ratio,serum lipase test,TNF-α,IL-10 changes.Results: AP group disease score pancreatitis,pancreatic/ body weight ratio,serum lipase,TNF-α,IL-10 was significantly higher than the control group(P0.01).Pancreas/body weight ratio in the 12 hours after modeling has been significantly increased,then the peak at 48 hours;the serum lipase and pancreatic TNF-α,IL-10 in the 12 hours after the model peak,then decline,but still maintain a high level.Candesartan pancreatitis patients in the experimental group intervention score,pancreas / body weight ratio,serum lipase,TNF-α and TNF-α pancreatic lower than the AP group(P0.05),but low dose candesartan group and high dose no significant difference between groups(P0.05).In this study,the application of candesartan on serum levels of AP and pancreatic IL-10 had no significant effect(P0.05).Conclusion: AT1 receptor antagonist candesartan can significantly reduce the L-arginine induced acute pancreatitis in inflammation and injury.